Vybrique

5. WARNINGS AND PRECAUTIONS . Patients should not use VYBRIQUE if sexual activity is inadvisable due to cardiovascular status. ( 5.1 ) Patients should seek emergency treatment if an erection lasts >4 hours. Use VYBRIQUE with caution in patients predisposed to priapism. ( 5.2 ) Patients should stop VYBRIQUE and seek medical care if a sudden loss of vision occurs in one or both eyes, which could be a sign of non-arteritic anterior ischemic optic neuropathy (NAION). VYBRIQUE should be used with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION. Patients with a “crowded” optic disc may also be at an increased risk of NAION. ( 5.3 ) Patients should stop VYBRIQUE and seek prompt medical attention in the event of sudden decrease or loss of hearing. ( 5.4 ) Caution is advised when VYBRIQUE is co-administered with alpha-blockers or antihypertensives. Concomitant use may lead to hypotension. ( 5.5 ) Decreased blood pressure, syncope, and prolonged erection may occur at higher sildenafil exposures. In patients taking strong CYP inhibitors such as ritonavir, sildenafil exposure is increased. Decrease in VYBRIQUE dosage is recommended. ( 2.2 , 5.6 ). 5.1 Cardiovascular Risk General There is a potential for cardiac risk of sexual activity in patients with preexisting cardiovascular disease. Therefore, treatments for erectile dysfunction, including VYBRIQUE should not be used in men for whom sexual activity is inadvisable because of their underlying cardiovascular status. The following groups of patients were not included in clinical safety and efficacy trials for sildenafil, and therefore, until further information is available, VYBRIQUE is not recommended for use in the following groups: Patients who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months Patients with resting hypotension (BP <90/50 mmHg) or hypertension (BP >170/110 mmHg) Patients with cardiac failure or coronary artery disease causing unstable angina. Blood Pressure Decreases Patients with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure can be sensitive to the actions of vasodilators, including VYBRIQUE. As with other PDE5 inhibitors, VYBRIQUE has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers. In healthy subjects aged 18 to 45 years, VYBRIQUE 100 mg resulted in mean maximal decreases relative to placebo of 6 mmHg systolic and 3 mmHg diastolic. In healthy subjects aged 65 years and older, VYBRIQUE 100 mg resulted in mean maximal decreases relative to placebo of 14 mmHg systolic and 8 mmHg diastolic [ see Clinical Pharmacology ( 12.2 ) ]. Prior to prescribing VYBRIQUE, carefully consider whether patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects, especially in combination with sexual activity. 5.2 Prolonged Erection and Priapism Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported infrequently since market approval of sildenafil. In the event of an erection that persists longer than 4 hours, instruct the patient to seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result. Use VYBRIQUE with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia). 5.3 Effects on the Eye Advise patients to stop use of all phosphodiesterase type 5 (PDE5) inhibitors, including VYBRIQUE and seek medical attention in the event of a sudden loss of vision in one or both eyes. Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision including permanent loss of vision, that has been reported rarely post-marketing in temporal association with the use of all PDE5 inhibitors. Based on published literature, the annual incidence of NAION is 2.5-11.8 cases per 100,000 in males aged 50 years and older. An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period. The results suggest an approximate 2-fold increase in the risk of NAION, with a risk estimate of 2.15 (95% CI 1.06, 4.34). A similar study reported a consistent result, with a risk estimate of 2.27 (95% CI 0.99, 5.20). Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies. Neither the rare post-marketing reports, nor the association of PDE5 inhibitor use and NAION in the observational studies, substantiate a causal relationship between PDE5 inhibitor use and NAION [see Adverse Reactions ( 6.2 ) ] . Consider whether patients with underlying NAION risk factors could be adversely affected by use of PDE5 inhibitors. Individuals who have already experienced NAION are at increased risk of NAION recurrence. Therefore, use PDE5 inhibitors, including VYBRIQUE with caution in these patients and only when the anticipated benefits outweigh the risks. Individuals with “crowded” optic disc are also considered at greater risk for NAION compared to the general population, however, evidence is insufficient to support screening of prospective users of PDE5 inhibitors, including VYBRIQUE, for this uncommon condition. Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the sildenafil citrate clinical trials, and use in these patients is not recommended. 5.4 Sudden Hearing Loss Advise patients to stop taking PDE5 inhibitors, including VYBRIQUE and seek prompt medical attention in the event of sudden decrease or loss of hearing. These events, which may be accompanied by tinnitus and dizziness, have been reported in temporal association to the intake of PDE5 inhibitors, including sildenafil. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [ see Adverse Reactions ( 6.1 , 6.2 ) ]. 5.5 Hypotension when Co-administered with Alpha-blockers or Antihypertensives Alpha-blockers Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers. PDE5 inhibitors, including sildenafil, and alpha-adrenergic blocking agents are both vasodilators with blood pressure lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may occur. In some patients, concomitant use of these two drug classes can lower blood pressure significantly [ see Drug Interactions ( 7.2 ) and Clinical Pharmacology ( 12.2 ) ] leading to symptomatic hypotension (e.g., dizziness, lightheadedness, fainting). Consider the following: Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor. Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors. In patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest dose [see Dosage and Administration ( 2.2 ) ] . In patients already taking an optimized dose of a PDE5 inhibitor, alpha-blocker therapy should be initiated at the lowest dose. Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure when taking a PDE5 inhibitor. Safety of combined use of PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular volume depletion and other antihypertensive drugs. Antihypertensives VYBRIQUE has systemic vasodilatory properties and may further lower blood pressure in patients taking antihypertensive medications. When amlodipine, 5 mg or 10 mg, and sildenafil 100 mg were orally administered concomitantly to hypertensive patients, mean additional blood pressure reductions of 8 mmHg systolic and 7 mmHg diastolic were noted [see Drug Interactions ( 7.3 ) and Clinical Pharmacology ( 12.2 ) ]. 5.6 Adverse Reactions with the Concomitant Use of Ritonavir The concomitant administration of the protease inhibitor ritonavir substantially increases serum concentrations of sildenafil (11-fold increase in AUC). Data from subjects exposed to high systemic levels of sildenafil are limited. Decreased blood pressure, syncope, and prolonged erection were reported in some healthy volunteers exposed to high doses of sildenafil (200-800 mg). To decrease the chance of adverse reactions in patients taking ritonavir, the maximum recommended dosage and dosing frequency of VYBRIQUE is 25 mg once in a 48-hour period [see Dosage and Administration ( 2.2 ), Drug Interactions ( 7.4 ), and Clinical Pharmacology ( 12.3 ) ]. 5.7 Combination with other PDE5 Inhibitors or Other Erectile Dysfunction Therapies The safety and efficacy of combinations of VYBRIQUE with other PDE5 inhibitors, including pulmonary arterial hypertension (PAH) treatments containing sildenafil or other treatments for erectile dysfunction, have not been studied. Such combinations may further lower blood pressure. Therefore, the use of such combinations is not recommended. 5.8 Effects on Bleeding There have been postmarketing reports of bleeding events in patients who have taken sildenafil. A causal relationship between sildenafil and these events has not been established. In humans, sildenafil has no effect on bleeding time when taken alone or with aspirin. However, in vitro studies with human platelets indicate that sildenafil potentiates the antiaggregatory effect of sodium nitroprusside (a nitric oxide donor). In addition, the combination of heparin and sildenafil had an additive effect on bleeding time in the anesthetized rabbit, but this interaction has not been studied in humans. The safety of sildenafil is unknown in patients with bleeding disorders and patients with active peptic ulceration. 5.9 Counseling Patients About Sexually Transmitted Diseases The use of VYBRIQUE offers no protection against sexually transmitted diseases. Counseling of patients about the protective measures necessary to guard against sexually transmitted diseases, including the Human Immunodeficiency Virus (HIV), should be considered.

6. ADVERSE REACTIONS The following are discussed in more detail in other sections of the labeling: Cardiovascular [see Warnings and Precautions ( 5.1 )] Prolonged Erection and Priapism [see Warnings and Precautions ( 5.2 )] Effects on the Eye [see Warnings and Precautions ( 5.3 )] Hearing Loss [see Warnings and Precautions ( 5.4 )] Hypotension when Co-administered with Alpha-blockers or Anti-hypertensives [see Warnings and Precautions ( 5.5 ) ] Adverse Reactions with the Concomitant Use of Ritonavir [see Warnings and Precautions 5.6 )] Combination with other PDE5 Inhibitors or Other Erectile Dysfunction Therapies [see Warnings and Precautions ( 5.7 ) ] Effects on Bleeding [see Warnings and Precautions ( 5.8 ) ] The most common adverse reactions reported in clinical trials (≥ 2%) of sildenafil are headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash. Most common adverse reactions (≥ 2%) include headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness and rash. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact IBSA Pharma Inc. at 1-800-587-3513 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Sildenafil was administered to over 3700 patients (aged 19-87 years) during pre-marketing clinical trials worldwide. Over 550 patients were treated for longer than one year. In placebo-controlled clinical studies, the discontinuation rate due to adverse reactions for sildenafil (2.5%) was not significantly different from placebo (2.3%). In fixed-dose studies, the incidence of some adverse reactions increased with dose. The type of adverse events in flexible-dose studies was similar to that for fixed dose studies. At doses above the recommended dose range, adverse reactions were similar to those detailed in Table 1 but generally were reported more frequently. Table 1: Adverse Reactions Reported by ≥2% of Patients Treated with Sildenafil and More Frequent than Placebo in Fixed-Dose Clinical Studies Adverse Reaction 25 mg (n=312) 50 mg (n=511) 100 mg (n=506) Placebo (n=607) Headache 16% 21% % 28 % 7 Flushing 10% 19% 18% 2% Dyspepsia 3% 9% 17% 2% Abnormal vision† 1% 2% 11% 1% Nasal congestion 4% 4% 9% 2% Back pain 3% 4% 4% 2% Myalgia 2% 2% 4% 1% Nausea 2% 3% 3% 1% Dizziness 3% 4% 3% 2% Rash 1% 2% 3% 1% †Abnormal Vision: Mild to moderate in severity and transient, predominantly color tinge to vision, but also increased sensitivity to light, or blurred vision. When sildenafil was taken as recommended (on an as-needed basis) in flexible-dose, placebo-controlled clinical trials of two to twenty-six weeks duration, patients took sildenafil at least once weekly, and the following adverse reactions were reported: Table 2 : Adverse Reactions Reported by ≥2% of Patients Treated with Sildenafil and More Frequent than Placebo in Flexible-Dose Clinical Studies Adverse Reaction Sildenafil N=734 Placebo N=725 Headache 16% 4% Flushing 10% 1% Dyspepsia 7% 2% Nasal Congestion 4% 2% Abnormal Vision† 3% 0% Back pain 2% 2% Dizziness 2% 1% Rash 2% 1% †Abnormal Vision: Mild to moderate in severity and transient, predominantly color tinge to vision, but also increased sensitivity to light or blurred vision. In these studies, only one patient discontinued due to abnormal vision. When VYBRIQUE was taken as recommended (on an as-needed basis) in a flexible-dose, placebo-controlled clinical trial of twelve weeks duration, patients took VYBRIQUE at least once weekly, not more than once per day, and the following adverse reactions were reported: Table 3: Adverse Reactions Reported by ≥2% of Patients Treated with VYBRIQUE and More Frequent than Placebo in a Flexible-Dose Clinical Study Adverse Reactions VYBRIQUE N=354 PLACEBO N=121 Headache 11% 4% Flushing 4% 0% Dyspepsia 4% 1% Nasal Congestion 3% 0% Dizziness 2% 0% In this study, none of the patients discontinued due to adverse reactions to VYBRIQUE. The following events occurred in <2% of patients in controlled clinical trials of sildenafil; a causal relationship to sildenafil is uncertain. Reported events include those with a plausible relation to drug use; omitted are minor events and reports too imprecise to be meaningful: Body as a Whole: face edema, photosensitivity reaction, shock, asthenia, pain, chills, accidental fall, abdominal pain, allergic reaction, chest pain, accidental injury. Cardiovascular: angina pectoris, AV block, migraine, syncope, tachycardia, palpitation, hypotension, postural hypotension, myocardial ischemia, cerebral thrombosis, cardiac arrest, heart failure, abnormal electrocardiogram, cardiomyopathy. Digestive: vomiting, glossitis, colitis, dysphagia, gastritis, gastroenteritis, esophagitis, stomatitis, dry mouth, liver function tests abnormal, rectal hemorrhage, gingivitis. Hemic and Lymphatic: anemia and leukopenia. Metabolic and Nutritional: thirst, edema, gout, unstable diabetes, hyperglycemia, peripheral edema, hyperuricemia, hypoglycemic reaction, hypernatremia. Musculoskeletal: arthritis, arthrosis, myalgia, tendon rupture, tenosynovitis, bone pain, myasthenia, synovitis. Nervous: ataxia, hypertonia, neuralgia, neuropathy, paresthesia, tremor, vertigo, depression, insomnia, somnolence, abnormal dreams, reflexes decreased, hypesthesia. Respiratory: asthma, dyspnea, laryngitis, pharyngitis, sinusitis, bronchitis, sputum increased, cough increased. Skin and Appendages: urticaria, herpes simplex, pruritus, sweating, skin ulcer, contact dermatitis, exfoliative dermatitis. Special Senses: sudden decrease or loss of hearing, mydriasis, conjunctivitis, photophobia, tinnitus, eye pain, ear pain, eye hemorrhage, cataract, dry eyes. Urogenital: cystitis, nocturia, urinary frequency, breast enlargement, urinary incontinence, abnormal ejaculation, genital edema and anorgasmia. Analysis of the safety database from sildenafil controlled clinical trials showed no apparent difference in adverse reactions in patients taking sildenafil with and without antihypertensive medication. This analysis was performed retrospectively and was not powered to detect any pre-specified difference in adverse reactions. 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of sildenafil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion either due to their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors. Cardiovascular and C erebrovascular : serious cardiovascular, cerebrovascular, and vascular events, including myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, hypertension, subarachnoid and intracerebral hemorrhages, and pulmonary hemorrhage have been reported post-marketing in temporal association with the use of sildenafil. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of sildenafil without sexual activity. Others were reported to have occurred hours to days after the use of sildenafil and sexual activity. It is not possible to determine whether these events are related directly to sildenafil, to sexual activity, to the patient’s underlying cardiovascular disease, to a combination of these factors, or to other factors [see Warnings and Precautions ( 5.1 ) and Patient Counseling Information ( 17 ) ]. Hemic and Lymphatic : vaso-occlusive crisis: In a small, prematurely terminated study of sildenafil in patients with pulmonary arterial hypertension (PAH) secondary to sickle cell disease, vaso-occlusive crises requiring hospitalization were more commonly reported in patients who received sildenafil than in those randomized to placebo. The clinical relevance of this finding to men treated with sildenafil for ED is not known. Nervous: seizure, seizure recurrence, anxiety, and transient global amnesia. Respiratory: epistaxis Special senses: Hearing: Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including sildenafil. In some of the cases, medical conditions and other factors were reported that may have also played a role in the otologic adverse events. In many cases, medical follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of sildenafil, to the patient’s underlying risk factors for hearing loss, a combination of these factors, or to other factors [ see Warnings and Precautions ( 5.4 ) , Patient Counseling Information ( 17 )]. Ocular: diplopia, temporary vision loss/decreased vision, ocular redness or bloodshot appearance, ocular burning, ocular swelling/pressure, increased intraocular pressure, retinal edema, retinal vascular disease or bleeding, and vitreous traction/detachment. Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil. Most, but not all, of these patients had underlying anatomic or vascular risk factors for developing NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia and smoking [see Warnings and Precautions ( 5.3 ) , Patient Counseling Information ( 17 ) ] . Urogenital : prolonged erection, priapism [ see Warnings and Precautions ( 5.2 ) and Patient Counseling Information ( 17 )], and hematuria.

<table><caption>Table 1: Adverse Reactions Reported by &#x2265;2% of Patients Treated with Sildenafil and More Frequent than Placebo in Fixed-Dose Clinical Studies</caption><col width="124"/><col width="65"/><col width="60"/><col width="69"/><col width="71"/><tbody><tr><td align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">Adverse Reaction</content></td><td align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">25 mg</content> <content styleCode="bold">(n=312)</content></td><td align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">50 mg</content> <content styleCode="bold">(n=511)</content></td><td align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">100 mg</content> <content styleCode="bold">(n=506)</content></td><td align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">Placebo</content> <content styleCode="bold">(n=607)</content></td></tr><tr><td align="center" styleCode="Toprule Lrule Rrule ">Headache</td><td align="center" styleCode="Toprule Lrule Rrule ">16%</td><td align="center" styleCode="Toprule Lrule Rrule ">21%</td><td align="center" styleCode="Toprule Lrule Rrule ">% 28</td><td align="center" styleCode="Toprule Lrule Rrule ">% 7</td></tr><tr><td align="center" styleCode="Toprule Lrule Rrule ">Flushing</td><td align="center" styleCode="Toprule Lrule Rrule ">10%</td><td align="center" styleCode="Toprule Lrule Rrule ">19%</td><td align="center" styleCode="Toprule Lrule Rrule ">18%</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td></tr><tr><td align="center" styleCode="Toprule Lrule Rrule ">Dyspepsia</td><td align="center" styleCode="Toprule Lrule Rrule ">3%</td><td align="center" styleCode="Toprule Lrule Rrule ">9%</td><td align="center" styleCode="Toprule Lrule Rrule ">17%</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td></tr><tr><td align="center" styleCode="Toprule Lrule Rrule ">Abnormal vision&#x2020;</td><td align="center" styleCode="Toprule Lrule Rrule ">1%</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td><td align="center" styleCode="Toprule Lrule Rrule ">11%</td><td align="center" styleCode="Toprule Lrule Rrule ">1%</td></tr><tr><td align="center" styleCode="Toprule Lrule Rrule ">Nasal congestion</td><td align="center" styleCode="Toprule Lrule Rrule ">4%</td><td align="center" styleCode="Toprule Lrule Rrule ">4%</td><td align="center" styleCode="Toprule Lrule Rrule ">9%</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td></tr><tr><td align="center" styleCode="Toprule Lrule Rrule ">Back pain</td><td align="center" styleCode="Toprule Lrule Rrule ">3%</td><td align="center" styleCode="Toprule Lrule Rrule ">4%</td><td align="center" styleCode="Toprule Lrule Rrule ">4%</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td></tr><tr><td align="center" styleCode="Toprule Lrule Rrule ">Myalgia</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td><td align="center" styleCode="Toprule Lrule Rrule ">4%</td><td align="center" styleCode="Toprule Lrule Rrule ">1%</td></tr><tr><td align="center" styleCode="Toprule Lrule Rrule ">Nausea</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td><td align="center" styleCode="Toprule Lrule Rrule ">3%</td><td align="center" styleCode="Toprule Lrule Rrule ">3%</td><td align="center" styleCode="Toprule Lrule Rrule ">1%</td></tr><tr><td align="center" styleCode="Toprule Lrule Rrule ">Dizziness</td><td align="center" styleCode="Toprule Lrule Rrule ">3%</td><td align="center" styleCode="Toprule Lrule Rrule ">4%</td><td align="center" styleCode="Toprule Lrule Rrule ">3%</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td></tr><tr><td align="center" styleCode="Toprule Lrule Rrule ">Rash</td><td align="center" styleCode="Toprule Lrule Rrule ">1%</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td><td align="center" styleCode="Toprule Lrule Rrule ">3%</td><td align="center" styleCode="Toprule Lrule Rrule ">1%</td></tr><tr><td colspan="5" styleCode="Toprule ">&#x2020;Abnormal Vision: Mild to moderate in severity and transient, predominantly color tinge to vision, but also increased sensitivity to light, or blurred vision.</td></tr></tbody></table>

<table><caption>Table 2 : Adverse Reactions Reported by &#x2265;2% of Patients Treated with Sildenafil and More Frequent than Placebo in Flexible-Dose Clinical Studies</caption><col width="133"/><col width="140"/><col width="138"/><tbody><tr><td styleCode="Toprule Lrule Rrule "><content styleCode="bold">Adverse Reaction</content></td><td align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">Sildenafil</content><content styleCode="bold"> </content> <content styleCode="bold">N=734</content></td><td align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">Placebo</content> <content styleCode="bold">N=725</content></td></tr><tr><td styleCode="Toprule Lrule Rrule ">Headache</td><td align="center" styleCode="Toprule Lrule Rrule ">16%</td><td align="center" styleCode="Toprule Lrule Rrule ">4%</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Flushing</td><td align="center" styleCode="Toprule Lrule Rrule ">10%</td><td align="center" styleCode="Toprule Lrule Rrule ">1%</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Dyspepsia</td><td align="center" styleCode="Toprule Lrule Rrule ">7%</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Nasal Congestion</td><td align="center" styleCode="Toprule Lrule Rrule ">4%</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Abnormal Vision&#x2020;</td><td align="center" styleCode="Toprule Lrule Rrule ">3%</td><td align="center" styleCode="Toprule Lrule Rrule ">0%</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Back pain</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Dizziness</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td><td align="center" styleCode="Toprule Lrule Rrule ">1%</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Rash</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td><td align="center" styleCode="Toprule Lrule Rrule ">1%</td></tr><tr><td colspan="3" styleCode="Toprule ">&#x2020;Abnormal Vision: Mild to moderate in severity and transient, predominantly color tinge to vision, but also increased sensitivity to light or blurred vision. In these studies, only one patient discontinued due to abnormal vision.</td></tr></tbody></table>

<table><caption>Table 3: Adverse Reactions Reported by &#x2265;2% of Patients Treated with VYBRIQUE and More Frequent than Placebo in a Flexible-Dose Clinical Study</caption><col width="141"/><col width="107"/><col width="112"/><tbody><tr><td align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">Adverse</content><content styleCode="bold">Reactions</content></td><td align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">VYBRIQUE</content> <content styleCode="bold">N=354</content></td><td align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">PLACEBO</content> <content styleCode="bold">N=121</content></td></tr><tr><td styleCode="Toprule Lrule Rrule ">Headache</td><td align="center" styleCode="Toprule Lrule Rrule ">11%</td><td align="center" styleCode="Toprule Lrule Rrule ">4%</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Flushing</td><td align="center" styleCode="Toprule Lrule Rrule ">4%</td><td align="center" styleCode="Toprule Lrule Rrule ">0%</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Dyspepsia</td><td align="center" styleCode="Toprule Lrule Rrule ">4%</td><td align="center" styleCode="Toprule Lrule Rrule ">1%</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Nasal Congestion</td><td align="center" styleCode="Toprule Lrule Rrule ">3%</td><td align="center" styleCode="Toprule Lrule Rrule ">0%</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Dizziness</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td><td align="center" styleCode="Toprule Lrule Rrule ">0%</td></tr></tbody></table>